News
-
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Heidelberg Pharma significantly reduces operating costs and focuses on lead ADC candidate HDP-101 due to delayed milestone payment. Extensive cost-saving measures implemented -
-
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Heidelberg Pharma announces new clinical data for lead ATAC candidate HDP-101 to be presented at the International Myeloma Society Annual Meeting 2025 -
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Heidelberg Pharma's partner Telix Pharmaceuticals faces delays in TLX250-CDx FDA approval. USD 70 million payment from HealthCare Royalty postponed. Current cash reach until Q1 2026 -
-
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Heidelberg Pharma AG reports on positive first half-year 2025 business performance including advancements in ATAC candidates HDP-101 and HDP-102. Financial figures show promising results in line with planning -
-
PRESS RELEASE
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Heidelberg Pharma dosed first patient in Phase I study of Amanitin-based ADC HDP-102 for Non-Hodgkin Lymphoma. ATAC technology targeting CD37. Promising data presented at AACR 2024
